Exploring Sirtuin 2 Inhibitors as Anti-Leishmanial Therapy Candidates: A Virtual Screening Approach (2025)
- Authors:
- Autor USP: JESUS, JULLYANE GABRYELLY DE - FCF
- Unidade: FCF
- Sigla do Departamento: FBC
- DOI: 10.11606/D.9.2025.tde-06022026-145313
- Subjects: LEISHMANIA; DOENÇAS NEGLIGENCIADAS; FARMACOCINÉTICA
- Keywords: Doenças Tropicais negligenciadas; Leishmania; SIR2RP1; Sirtuína 2; Triagem virtual
- Agências de fomento:
- Language: Inglês
- Abstract: Leishmaniasis is a neglected tropical disease that causes significant morbidity and mortality worldwide. Current treatments are limited by toxicity, high cost, and low efficacy, reinforcing the need for safer and more selective therapeutic alternatives. Sirtuin 2 (SIR2RP1), an NAD+-dependent deacetylase, plays essential roles in the physiology and survival of protozoa of the genus Leishmania, making it a promising target for drug development. This study focuses on identifying and evaluating potential inhibitors of Leishmania SIR2RP1 using in silico methods. Known sirtuin inhibitors are systematically analyzed based on their selectivity indices (SI), therapeutic indices (TI), and drug-likeness profiles to prioritize the most promising candidates. Through this comparative analysis, N-(2-Fluorophenyl)nicotinamide (NmoF) emerges as the reference compound due to its outstanding selectivity for Leishmania sirtuins and favorable molecular properties. Based on this prioritization, a ligand-based virtual screening (LBVS) of 460,160 compounds from the Enamine Hit Locator Library (HLL-460) is carried out using ROCS/VROCS to identify novel compounds that are structurally and electrostatically similar to NmoF. This targeted screening identifies 7 new molecules with high selectivity and potential inhibitory activity against Leishmania SIR2RP1. Hits are evaluated for their ADMET (absorption, distribution, metabolism, excretion, and toxicity) properties to assess pharmacokinetic and safety profiles. Overall, this study aims to propose new candidate compounds for development as selective anti-Leishmania agents, contributing to the search for safer and more effective treatments against leishmaniasis.
- Imprenta:
- Data da defesa: 14.11.2025
- Status:
- Artigo publicado em periódico de acesso aberto (Gold Open Access)
- Versão do Documento:
- Versão publicada (Published version)
- Acessar versão aberta:
-
ABNT
JESUS, Jullyane Gabryelly de. Exploring Sirtuin 2 Inhibitors as Anti-Leishmanial Therapy Candidates: A Virtual Screening Approach. 2025. Dissertação (Mestrado) – Universidade de São Paulo, São Paulo, 2025. Disponível em: https://teses.usp.br/teses/disponiveis/9/9143/tde-06022026-145313/. Acesso em: 02 abr. 2026. -
APA
Jesus, J. G. de. (2025). Exploring Sirtuin 2 Inhibitors as Anti-Leishmanial Therapy Candidates: A Virtual Screening Approach (Dissertação (Mestrado). Universidade de São Paulo, São Paulo. Recuperado de https://teses.usp.br/teses/disponiveis/9/9143/tde-06022026-145313/ -
NLM
Jesus JG de. Exploring Sirtuin 2 Inhibitors as Anti-Leishmanial Therapy Candidates: A Virtual Screening Approach [Internet]. 2025 ;[citado 2026 abr. 02 ] Available from: https://teses.usp.br/teses/disponiveis/9/9143/tde-06022026-145313/ -
Vancouver
Jesus JG de. Exploring Sirtuin 2 Inhibitors as Anti-Leishmanial Therapy Candidates: A Virtual Screening Approach [Internet]. 2025 ;[citado 2026 abr. 02 ] Available from: https://teses.usp.br/teses/disponiveis/9/9143/tde-06022026-145313/
Informações sobre a disponibilidade de versões do artigo em acesso aberto coletadas automaticamente via oaDOI API (Unpaywall).
Por se tratar de integração com serviço externo, podem existir diferentes versões do trabalho (como preprints ou postprints), que podem diferir da versão publicada.
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
